5nance5nance
5nance5nance
HomeScreens
LOGINGET FREE ACCOUNT

Strides Pharma Science Ltd.

•
strides.comBSE: 532531NSE: STAR
Market Cap₹ 10,933 Cr.
Current Price
High / Low₹ 1,231 / 769
Stock P/E17.8
Book Value₹ 355
Price to Book2.78
Dividend Yield0.42 %
ROCE18.6 %
ROE20.3 %
Face Value₹ 10

Add ratio to table

ABOUT

KEY POINTS

Revenue Breakup Mar 2024 • Pharma: 100.0%

AI Sector View

AI GENERATED

Healthcare

Buy

This stance relies on proxies and positioning because no direct pharma-export or healthcare operating series exists in the dataset. The depreciated currency at 95.23 (Sep/26) can support export earnings, inflation at 4.45% (Jul/26) is manageable for a defensive sector, and consumer spending remains large at INR 44743 billion (Jun/26). Strong FPI inflow of INR 10620 crore over 3 months to 2026-08-31 from INR -11381 crore in the prior 3 months adds a real sector-specific tailwind, but confidence stays capped because the fundamental drivers are indirect proxies.

Confidence
50%
View full sector analysis →

PROS

  • Promoters have been increasing their shareholding - up 2.1pp over 2 years
  • Latest quarter profit grew 56.7% YoY, showing strong momentum
  • Strong cash generation - operating cash flow backs reported profits (CFO/PAT 2.49x)
  • Operating margins have improved to 11.9% from 8.3%
  • Company generates healthy free cash flow
  • Institutional investors have been accumulating - FII+DII up 2.5pp

CONS

  • A large part of profit comes from other income (34.6% of PBT)
  • Recurring exceptional / one-off items are inflating headline profit
  • Company has delivered a poor sales growth of 7.9% over past five years

* The pros and cons are machine generated based on quantitative rules.

Peer comparison

HealthcareHealthcarePharmaceuticals & Drugs
Part ofNIFTY MICROCAP250NIFTY TOTAL MKT
S.No.Name
1.SUNPHARMA1842.0036.54441957.500.872901.2326.5315299.8810.9819.1128.81
2.DIVISLAB9326.0084.64247576.000.32902.0065.503080.0027.8021.5140.75
3.TORNTPHARM4975.0086.76189233.010.76566.003.284921.0057.3219.2733.81
4.ZYDUSLIFE1119.5024.74111670.550.09990.20-34.908017.0023.9721.3924.54
5.CIPLA1365.0032.72110272.680.95785.55-39.187119.284.1316.0016.73
6.LAURUSLABS1970.3597.37106460.420.10362.07123.942026.3129.1018.2031.50
7.DRREDDY1161.0030.0796906.380.69435.60-69.108099.80-5.2113.7510.63
8.AUROPHARMA1675.4525.9796401.690.241032.0325.229150.3517.4412.7620.54
9.LUPIN2096.0017.3495842.920.861416.9816.018276.8934.2828.8629.59
10.MANKIND2277.0046.0494050.370.04574.0929.124030.5912.8913.2426.30
11.GLENMARK2416.9037.9468210.880.10482.83927.884018.4831.3520.3520.03
12.STAR1186.1017.8210932.610.42165.4956.731265.4113.0118.5718.06
Detailed Comparison with:

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
9309991,0061,0441,0541,1671,1541,1901,1201,2211,1951,3231,265
7638468648398649829439739029899591,0841,133
Operating Profit167153142204190185210218218232236240133
OPM %17.91%15.32%14.12%19.58%18.02%15.82%18.23%18.30%19.48%18.97%19.75%18.11%10.50%
3-129-1-22111253-150181042-58
Interest76797071737452504746434241
Depreciation60604948474848494950515356
Profit before Tax33-115226418287113103122154246147200
Tax %29.11%6.49%73.19%19.67%10.45%16.05%21.09%20.11%13.49%14.00%15.21%12.80%17.09%
Net Profit0000683949086106132208129165
-0.79-14.54-1.222.6017.777.819.568.9210.8113.8421.9313.7717.02

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
2,7552,8452,1782,7523,3163,0703,6883,8904,5654,8595,004
2,2282,4431,9362,2362,6893,0923,3033,3183,7684,0144,164
Operating Profit527402242516627-22385572798845840
OPM %19.14%14.14%11.12%18.75%18.90%-0.70%10.45%14.71%17.47%17.38%16.79%
1254562-25103-110118-13912820565
Interest18319679156150177261280249179172
Depreciation126154117174206233243214192202210
Profit before Tax343806255275-653-286-115487669746
Tax %18.48%7.11%-43.04%20.71%11.49%27.32%19.32%-25.36%15.92%14.08%14.99%
Net Profit280748943244-474-231-144409575634
EPS44.6474.2336.244.0629.92-51.28-22.49-7.68389.9060.34—
Dividend Payout %10.07%2.69%8.28%344.56%8.35%0.00%-6.68%-32.54%1.03%8.29%—

COMPOUNDED SALES GROWTH

10 Years:
5%
5 Years:
8%
3 Years:
10%

COMPOUNDED PROFIT GROWTH

10 Years:
18%
5 Years:
16%
3 Years:
—

STOCK PRICE CAGR

10 Years:
—
5 Years:
—
3 Years:
—
1 Year:
30%

RETURN ON EQUITY

10 Years:
3%
5 Years:
1%
3 Years:
10%
Last Year:
20%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Corporate actions

2026

Jul 31

₹ 0.50

Rs.5.0000 per share(50%)Final Dividend

2025

Jul 22

₹ 0.40

Rs.4.0000 per share(40%)Final Dividend

2024

Sep 9

₹ 0.25

Rs.2.5000 per share(25%)Final Dividend

2023

Aug 4

₹ 0.15

Rs.1.5000 per share(15%)Final Dividend

2021

Aug 5

₹ 0.25

Rs.2.5000 per share(25%)Final Dividend

2018

Sep 12

₹ 0.20

Rs.2.0000 per share(20%)Final Dividend

2017

Sep 7

₹ 0.45

Rs.4.5000 per share(45%)Dividend

2016

Jul 21

₹ 0.40

Rs.4.0000 per share(40%)Dividend

2026

Jul 21

₹ 0.50

Rs.5.0000 per share(50%)Final Dividend

Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital89909090909090929292
Minority Interest134155153673724-39-543542
2,6512,3652,5522,4322,6822,2672,1032,0312,4593,015
4,1262,9223,6712,2852,3913,0342,9892,3801,7741,675
Trade Payables7747128897981,1341,0729828521,0321,310
261342453281483275249272387510
Total Liabilities8,0356,5857,8075,9536,8176,7616,3735,5725,7806,643
2,9092,9033,5702,0262,1512,3332,2981,8531,8882,100
Capital Work in Progress204322100148228564880100161
1,525588702549697540490303409291
7335528747831,2011,1741,1471,1261,2781,635
00000001,1421,2031,289
Cash & Bank329303517237180187316191137213
2,3341,9172,0452,2102,3602,4702,074877765954
Total Assets8,0356,5857,8075,9536,8176,7616,3735,5725,7806,643

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
347241116250325-260-43701684703
Cash from Investing-687583-1481,306-521-119302-150-90-173
Cash from Financing338-1,016194-1,709-16421-214-693-643-453
-60-246106-199-5545133-143-4876

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026

Shareholding Pattern

Numbers in percentages

Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
25.8625.8426.8228.3028.3027.8627.8627.9127.91
26.7130.0828.4828.3228.0228.5129.5228.6828.40
18.1718.2416.9213.7213.3012.9813.0214.4415.42
0.010.010.010.010.010.010.010.010.01
28.8725.8327.7729.6530.3730.6429.5928.9528.28

Documents

Corporate disclosures, annual reports, credit ratings, and concall transcripts

2026-09-11
General Updates

2026-09-11 - Strides Pharma Science Limited has informed the Exchange about completion of USFDA Inspection at the Company s Formulations Facility at Alathur

2026-08-19
Press Release

2026-08-19 - Strides Pharma Science Limited has informed the Exchange regarding a press release dated August 19, 2026, titled "Strides receives USFDA Establishment Inspection Report (EIR) for flagship facility in Bengaluru".

2026-08-18
Shareholders meeting

2026-08-18 - Strides Pharma Science Limited has submitted the Exchange a copy Srutinizers report of Annual General Meeting held on August 14, 2026. Further, the company has informed the Exchange regarding voting results.

2026-08-14
Shareholders meeting

2026-08-14 - Strides Pharma Science Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on August 14, 2026

2026-08-03
Analysts/Institutional Investor Meet/Con. Call Updates

2026-08-03 - Strides Pharma Science Limited has informed the Exchange about Transcript of Earnings Call pertaining to Unaudited Financial Results of the Company for the quarter ended June 30, 2026.

2026-08-01
Copy of Newspaper Publication

2026-08-01 - Strides Pharma Science Limited has informed the Exchange about Copy of Newspaper Publication- Unaudited Financial Results for the quarter ended June 30, 2026

2026-07-31
Analysts/Institutional Investor Meet/Con. Call Updates

2026-07-31 - Strides Pharma Science Limited has informed the Exchange about the link for Earnings Call pertaining to unaudited financial results for Q1 FY27

2026-07-31
General Updates

2026-07-31 - Strides Pharma Science Limited has informed the Exchange about Investor Presentation for Earnings call on Q1 FY 2027

2026-07-31
Press Release

2026-07-31 - Strides Pharma Science Limited has informed the Exchange regarding a press release dated July 31, 2026, titled "Strides Delivers Steady Performance with Q1FY27; Revenue at ₹12,654m, Grew 13% YoY; Ex-US Markets Grew 17% YoY".

News

Recent coverage and analyst commentary for STAR

Loading news…

🤖

AI Stock Analyst

Strides Pharma Science Ltd.

🔒

Sign in to Chat with AI

Log in with your 5nance account to ask institutional questions about performance, financials, and outlook.

✨ Sign In to Chat

Free 5nance Account

5nance5nance

Stock analysis and screening tool

5nanceAI © 2020-2026

Made with ❤️ in India.

Data provided by Accord Fintech

Terms & Privacy.

Product

PremiumWhat's new?Learn

Team

About usSupport

Theme

5nance5nance

Product

PremiumWhat's new?Learn

Team

About usSupport

Theme

5nanceAI © 2020-2026

Data provided by Accord Fintech

Made with ❤️ in India.

HomeScreens
Login